DB06621ExperimentalOrganism Based Therapies
ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase...
- Primary indication
- Investigated for use/treatment in scleroderma.Curator reviewed
- Code names
- ARG201
Which companies are running trials of ARG201, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account